Considerations for the Design of Toxicity Studies of Inhaled Nanomedicines

Nanotoxicity: From In Vivo and In Vitro Models to Health Risks

Volumn , Issue , 2009, Pages 41-60

  Dailey, Lea Ann ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Inhaled nanomedicines and toxicity study design; Lung retention times of drug control research; Nanoparticulate drug carrier system and cell or cell organelle access; Nanoparticulate pulmonary drug delivery; Nanotechnology and healthcare applications; Nanotechnology exploitation and inhalation therapy improvement; Particle surface chemistry and slowing clearance by MPS; Quantum dots imaging contrast agents in diagnostic applications; Respiratory nanotoxicology and inhaled nanomedicine research; Surface acoustic wave energy for monodisperse nanoparticles

Indexed keywords

EID: 82255188637     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470747803.ch3     Document Type: Chapter

References (45)

1. Bailey MM, Berkland CJ (2008) Nanoparticle formulations in pulmonary drug delivery. Med Res Rev 29, 196-212.
2. Bihari P, Vippola M, Schultes S, Praetner M, Khandoga AG, Reichel CA, Coester C, Tuomi T, Rehberg M, Krombach F (2008) Optimized dispersion of nanoparticles for biological in vitro and in vivo studies. Part Fibre Toxicol 5: 14.
3. Birnbaum DT, Brannon-Peppas L (2003) Molecular weight distribution changes during degradation and release of PLGA nanoparticles containing epirubicin HCl. J Biomater Sci Polymer Edn 14, 87-102.
4. Black C, Cummins E, Royle P, Philip S, Waugh N (2007) The clinical effectiveness and costeffectiveness of inhaled insulin in diabetes mellitus: a systematic review and economic evaluation. Health Technol Assess 11(33), 1-126.
5. Borm JA, KreylingW (2004) Toxicological hazards of inhaled nanoparticles-potential implications for drug delivery. J Nanosci Nanotech 4(6), 1-11.
6. Buzea C, Pacheco Blandino II, Robbie K (2007) Nanomaterials and nanoparticles: sources and toxicity. Biointerphases 2(4), MR17-MR172.
7. Card JW, Zeldin DC, Bonner JC, Nestmann ER (2008) Pulmonary applications and toxicity of engineered nanoparticles. Am J Physiol Lung Cell Mol Physiol 295, L400-L411.
8. Chattopadhyay P, Shekunov BY, Yimb D, Cipolla D, Boyd B, Farr S (2007) Production of solid lipid nanoparticle suspensions using supercritical fluid extraction of emulsions (SFEE) for pulmonary delivery using the AERx system R®. Adv Drug Del Rev 59, 444-453.
9. Cooke RW, Drury JA (2005) Reduction of oxidative stress marker in lung fluid of preterm infants after administration of intra-tracheal liposomal glutathione. Biol Neonate 87, 178-180.
10. Costigan S (2006) The toxicology of nanoparticles used in health care products. Medicines and Healthcare Products Regulatory Agency, Department of Health, UK. Available at http:www.mhra.gov.uk/home/idcplg?IdcService=SSGETPAGE&nodeId=996, [accessed 21 October 2008].
11. Dailey LA, Kleemann E, Wittmar M, Gessler T, Schmehl T, Roberts C, Seeger W, Kissel T (2003a) Surfactant-free, biodegradable nanoparticles for aerosol therapy based upon the branched polyesters, DEAPA-PVAL-g-PLGA. Pharm Res 20, 2011-2020.
12. Dailey LA, Schmehl T, Gessler T, Grimminger W, Seeger W, Kissel T (2003b) Nebulization of biodegradable nanoparticles: impact of nebulizer technology and nanoparticle characteristics on aerosol features. J Controlled Release 86, 131-144.
13. Dailey LA, Jekel N, Fink L, Gessler T, Schmehl T, Wittmar M, Kissel T, Seeger W (2006) Investigation of the proinflammatory potential of biodegradable nanoparticle drug delivery systems in the lung. Toxicol Appl Pharmacol 215, 100-108.
14. De Jong WH, Borm PJA (2008) Drug delivery and nanoparticles: applications and hazards. Int J Nanomed 3, 133-149.
15. Durcan N, Murphy C, Cryan SA (2008) Inhalable siRNA: potential as a therapeutic agent in the lungs. Mol Pharm 5, 559-566.
16. Friend JR,YeoLY,Arifin DR,MechlerA (2008) Evaporative self-assembly assisted synthesis of polymeric nanoparticles by surface acoustic wave atomization. Nanotechnology 19, 145301-145307.
17. Gelperina S, Kisich K, Iseman MD, Heifets L (2005) The potential advantages of nanoparticle drug delivery systems in chemotherapy of tuberculosis. Am J Respir Crit Care Med 172, 1487-1490.
18. Grenha A, Grainger C, Dailey LA, Seijo B, Martin GP, Remuñán-López C, Forbes B (2007) Compatibility of microencapsulated chitosan nanoparticles with respiratory epithelial cell layers. Eur J Pharm Sci 31, 73-84.
19. Gul MO, Jones SA, Dailey LA, Nacer H, Ma Y, Sadouli F, Hider RC, Araman A, Forbes B (2009) A poly(vinyl alcohol) nanoparticle platform for kinetic studies of inhaled nanoparticles. Inhal Toxicol 23 March, 1-10.
20. Hawkins MJ, Soon-Shiong P, Desai N (2008) Protein nanoparticles as drug carriers in clinical medicine. Adv Drug Deliv Rev 60, 876-885.
21. Hochhaus G, Suarez S, Gonzalez-Rothi RJ, Schreier H (1998) Pulmonary targeting of inhaled glucocorticosteroids: how is it influenced by formulation? Resp Drug Del VI, 45-52.
22. Hoet PHM, Brüske-Hohlfeld I, Salata OV (2004) Nanoparticles-known and unknown health risks. J Nanobiotech 2. Available at http://www.jnanobiotechnology.com/content/2/1/12.
23. Kelly HW (2003) Potential adverse effects of inhaled corticosteroids. J Allergy Clin Immunol 112, 469-478.
24. Kumar CSSR (ed.) (2007b) Nanomaterials forMedical Diagnosis and Therapy, Nanotechnologies for the Life Sciences (Band 10). Wiley-VCH: Weinheim.
25. Leroueil PR, Hong S, Mecke A, Baker JR Jr, Orr BG, Banazak Holl MM (2007) Nanoparticle interaction with biological membranes: does nanotechnology present a Janus face? Acc ChemRes 40, 335-342.
26. Lewis TR, MorrowPE, McClellanRO, Raabe OG,Kennedy GL, SchwetzBA, Goehl TJ, Roycroft JH, Chhabra RS (1989) Establishing aerosol exposure concentrations for inhalation toxicity studies. Tox Appl Pharmacol 99, 377-383.
27. Liu J, Gong T, Fu H, Wang C, Wang X, Chen Q, Zhang Q, He Q, Zhang Z (2008) Solid lipid nanoparticles for pulmonary delivery of insulin. Int J Pharm 356, 333-344.
28. Lombry C, Edwards DA, Préat V, Vanbever R (2004) Alveolar macrophages are a primary barrier to pulmonary absorption of macromolecules. Am J Physiol Lung Cell Mol Physiol 286, L1002-L1008.
29. Moghimi SM, Hunter AC, Murray JC (2001) Long-circulating and target-specific nanoparticles: theory to practice. Pharmacol Rev 53, 283-318.
30. Monteiro-Riviere NA, Tran CL (eds) (2007b) Nanotoxicology: Characterization, Dosing and Health Effects. Informa Healthcare: New York.
31. Morrow PE (1986) The setting of particulate exposure levels for chronic inhalation toxicity studies. Int J Toxicol 5, 533-544.
32. MozafariMR(ed.) (2006b) Nanocarrier Technologies: Frontiers of Nanotherapy. Springer: Dordrecht.
33. Radomska-Soukharev A (2007) Stability of lipid excipients in solid lipid nanoparticles. Adv Drug Deliv Rev 59, 411-418.
34. Schanker LS, Burton JA (1976) Absorption of heparin and cyanocobalamin from the rat lung. Proc Soc Exp Biol Med 152, 377-380.
35. Scientific Committee on Emerging and Newly Identified Health Risks (SCENIHR) (2006) The appropriateness of existing methodologies to assess the potential health risks associated with engineered and adventitious products of nanotechnologies. European Commission Health & Consumer Protection Directorate-General, SCENIHR/002/005. Available at http://ec.europa.eu/health/phrisk/committees/04scenihr/docs/scenihro003.pdf [accessed 12 October 2008].
36. Skubitz KM, Anderson PM (2000) Inhalational interleukin-2 liposomes for pulmonary metastases: a phase I clinical trial. Anticancer Drugs 11, 555-563.
37. Smola M, Vandamme T, Sokolowski A (2008) Nanocarriers as pulmonary drug delivery systems to treat and diagnose respiratory and non respiratory diseases. Int J Nanomed 3, 1-19.
38. Sung JC, Pulliam BL, Edwards DA (2007) Nanoparticles for drug delivery to the lungs. TRENDS Biotech 25, 563-570.
39. Takada K, Yamamoto M, Asada S (1978) Evidence for the pulmonary absorption of fluorescent labelled macromolecular compounds. J Pharm Dyn 1, 281-287.
40. Thomas M, Lu JJ, Chen J, Klibanov AM (2007) Non-viral siRNA delivery to the lung. Adv Drug Del Rev 59, 124-133.
41. Videira MA, Botelho MF, Santos AC, Gouveia LF, Pedroso de Lima JJ, António AJ (2002) Lymphatic uptake of pulmonary delivered radiolabelled solid lipid nanoparticles. J Drug Targeting 10, 607-613.
42. Warheit DB (2008) How meaningful are the results of nanotoxicity studies in the absence of adequate material characterization? Toxicol Sci 101, 183-185.
43. Wijagkanalan W, Higuchi Y, Kawakami S, Teshima M, Sasaki H, Hashida M (2008) Enhanced anti-inflammation of inhaled dexamethasone palmitate using mannosylated liposomes in an endotoxin-induced lung inflammation model. Mol Pharmacol 74, 1183-1192.
44. Wittmaack K (2007) In search of the most relevant parameter for quantifying lung inflammatory response to nanoparticle exposure: particle number, surface area, or what? EnvironHealth Perspect 115, 187-194.
45. Yang W, Peters JI, Williams RO (2008) Inhaled nanoparticles-a current review. Int J Pharm 356, 239-247.